Injectsense and Solid-State Microbattery Partner Injectpower Secure $9.4M for Implantable Device Supply Chain and Support of Clinical Studies
Summary
EMERYVILLE, Calif. and GRENOBLE, France, Nov. 15, 2023 /PRNewswire/ -- Injectsense Inc., a sensor-enabled digital health company, and sister company Injectpower, a developer of ultra-miniature solid-state microbatteries for medical applications, today announced combined funding of $9.4 million to bring highly integrated autonomous implantable devices smaller than a grain of rice -- to production.The implantable sensors, which monitor key indicators over decades, offer a disruptive capability at a time when most diagnostic tools are a mere static snapshot. Injectsense sensors measure IOP continuously, even during sleep, when pressure can spike significantly and cause vision loss over the long term.The funds will serve to further consolidate the two companies combined global supply infrastructure to create an advanced medical device cluster for implantables based in France. The cluster will streamline business opportunities, enable improved supply chain management, and support Injectsenses February 2024 first-in-human studies for sensors that continuously measure intraocular pressure (IOP).Injectsense already produces hundreds of prototype devices and is ramping up to thousands in 2024. The iOP-Connect data analysis software will identify clinically actionable information based on parameters specified by the physician.Injectpower funding comes from private and commercial investors that include the IDEC Group, business angels from the French Silicon Valley as well as Bpifrance and banking partners. The batteries are safe and among the smallest and most integrated on the market today, offering energy densities 5 to 10 times greater than current commercial capability, high reliability and a lifetime of several thousands of cycles.